Mangoceuticals Q1 Revenue Down 37.9% to $67.8K; Net Loss Improves to $(3.4M)
Mangoceuticals reported a significant decrease in Q1 2026 revenue and gross profit compared to the prior year, with revenue falling 37.9% to $67,864. Despite this, the company's net loss improved by 29.7% to $(3.4) million, primarily due to a substantial reduction in operating expenses. Cash and cash equivalents declined sharply to $174,562 from $1.49 million at year-end 2025, with no cash generated from financing activities in the quarter. The company also detailed corporate actions from early 2025, including the establishment of Series A Super Majority Voting Preferred Stock for its subsidiary Mango & Peaches Corp., and the assignment of key agreements to this subsidiary, granting its CEO, Jacob Cohen, 51% voting control.
Key Highlights
- Q1 2026 revenue decreased 37.9% to $67,864 from $109,306 in Q1 2025.
- Net loss improved 29.7% to $(3,403,150) in Q1 2026 from $(4,839,391) in Q1 2025.
- Basic and diluted loss per share improved to $(0.22) in Q1 2026 from $(1.12) in Q1 2025.
- Total operating expenses decreased 31.9% to $3,155,327 in Q1 2026.
- Cash and cash equivalents declined to $174,562 as of March 31, 2026, from $1,486,338 at December 31, 2025.
- No cash was provided by financing activities in Q1 2026, compared to $2,285,000 in Q1 2025.
- CEO Jacob Cohen gained 51% voting control of subsidiary Mango & Peaches Corp. in early 2025.
Price Impact
More from MGRX